J&J pulls bid for Pfizer consumer biz, GSK, Reckitt remain

Jan 26, 2018


Johnson & Johnson has removed itself from the race to buy Pfizer’s consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, says Reuters sources.

Potential buyers have until Feb. 1 to submit their non-binding offers for the unit. While Pfizer has not spoken publicly about the details of the sale, inside sources say the drugmaker is looking to fetch no less than $20 billion.

The deal -- which would include products such as Advil painkiller, Centrum multivitamins, Chapstick lip balm, and Robitussin cough medicine -- would be huge for rival drugmaker GSK or consumer goods group Reckitt, launching them into a top global spot in the consumer health business.

Read the Reuters coverage 


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments